期刊文献+

尾加压素ⅡmRNA在正常肾上腺髓质和嗜铬细胞瘤组织中的表达 被引量:4

Expression of urotensin II mRNA in normal adrenal medulla and pheochromocytoma tissues
原文传递
导出
摘要 目的 研究尾加压素Ⅱ (UrotensinⅡ ,UⅡ )mRNA在正常肾上腺髓质和嗜铬细胞瘤组织中的表达。方法 正常肾上腺髓质组织取自 9例意外死亡的中青年 ,嗜铬细胞瘤组织取自 19例患者手术切除标本 ,分别提取组织总RNA ,用逆转录 聚合酶链反应方法进行研究 ,以UⅡ和内参照GAPDH(甘油醛 3 三磷酸脱氢酶 )进行同管扩增 ,以扩增的目的条带灰度和内参照条带灰度比值UⅡ /GAPDH进行UⅡmRNA表达的半定量分析。结果 UⅡ的PCR扩增产物长度为 385bp ,测序结果与GeneBank所登记碱基序列相同率为 99.7%。正常肾上腺髓质和嗜铬细胞瘤组织UⅡ /GAPDH比值分别为 0 .6 9± 0 .2 9和 0 .2 2± 0 .18(P <0 .0 5 )。结论 UⅡmRNA在正常肾上腺髓质和嗜铬细胞瘤组织中均有表达 ,嗜铬细胞瘤组织中的表达低于正常肾上腺髓质组织。 Objective To investigat the expression of human urotensin II(UII)mRNA in normal adrenal medulla and pheochromocytoma tissues. Methods The total RNA of normal adrenal medulla from 9 males who died of accidents and the total RNA of pheochromocytoma tissues resected from 19 patients were extracted. The expression of UII mRNA was studied by reverse transcription-polymerase chain reaction (RT-PCR). UII and its internal control GAPDH were co-amplified in the same tube. Semi-quantitative analysis of the mRNA expression level of UII was carried out based on the ratios of the grey scale of the amplified target band to that of the control band (UII/GAPDH). Results The amplified product of UII is a 385 bp fragment and 99.7% of the bases were the same as the sequence registered in the GenBank. The UII/GAPDH in the normal adrenal medullae and pheochromocytomas were 0.69±0.29 (n=9) and 0.22±0.18 (n=19) respectively (P<0.05). Conclusion Both the normal adrenal medulla and pheochromocytoma express UII mRNA. The expression of UII mRNA is lower in pheochromocytoma than in normal adrenal medulla.
出处 《中华医学杂志》 CAS CSCD 北大核心 2003年第14期1225-1228,共4页 National Medical Journal of China
基金 首都医学发展科研基金部分资助项目 (首都ZD19990 8)
关键词 尾加压素Ⅱ 肾上腺髓质 嗜铬细胞瘤 逆转录-聚合酶链反应 缩血管物质 Adrenal gland Peochromocytoma Urotensin II
  • 相关文献

参考文献6

  • 1Pearson D, Shively JE, Clark BR,et al. UrotensinⅡ: a somatostatin-like peptide in the caudal neurosecretory system of fishes.Proc Natl Acad Sci U S A,1980,77:5021-5024.
  • 2Ames RS, Sarau HM, Chambers JK,et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for theorphan receptor GPR14.Nature,1999,401:282-286.
  • 3Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA,1998,95:15803-15808.
  • 4Douglas SA,Tayara L,Ohistein EH,et al.Congestive heart failure and expression of myocardial urotensin Ⅱ. Lancet,2002,359:1990-1997.
  • 5Ng LL, Loke I, O′Brien RJ,et al. Plasma urotensin in human systolic heart failure. Circulation,2002,106:2877-2880.
  • 6Heller J, Schepke M, Neef M, et al. Increased urotensin Ⅱ plasma levels in patients with cirrhosis and portal hypertension. J Hepatol,2002 ,37:767-772.

同被引文献34

  • 1刘彤华,陈原稼,武莎菲,高洁,蒋卫君,卢朝辉,关键,魏拴增,罗玉凤,曹金玲,万建伟.良性和恶性嗜铬细胞瘤的区别[J].中华病理学杂志,2004,33(3):198-202. 被引量:29
  • 2刘伯英,于忠和,郝淑玲.低氧大鼠血浆和支气管肺泡灌洗液尾加压素Ⅱ的变化[J].第三军医大学学报,2004,26(19):1742-1744. 被引量:16
  • 3Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedulin : a novel hypotensive peptide isolated from human pheochromocytoma.Biochem Biophys Res Commun, 1993, 192:553-560.
  • 4Coulouarn Y, Librman I, Jegou S, et al. Cloning of cDNA encoding the urotensin-II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 1998, 95:15803-15808.
  • 5Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin- II in human pulmonary and abdominal resistance arteries. Am J Heart Circ Physiol, 2001,250:925-925.
  • 6Rabinnovitch M, Bothwell T, Hayakawa BN, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defect and pulmonary hypertension :a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest, 1986,55:632-653.
  • 7Adatia I, Barrow SE, Stratton PD, et al. Thromboxane-A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation, 1993, 88:2117-2122.
  • 8Penny WF, Weinstein M, Salsman EW, et al. Correlation of circulating von willebrand factor levels with cardiovascular hemodynamics. Circulation, 1991,83 : 1630-1636.
  • 9Jougasaki M, Bumett JC. Adrenomedulin: Potential in physiology and pathophysiology. Life Sci, 2000, 66:855-872.
  • 10Nakamura M, Yoshika H, Makita S, et al. The various biological effects of adrenomedulin. Circulation, 1997, 95:1214-1221.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部